HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gribben, J. G. Search for Related Content PubMed PubMed Citation Articles by Gribben, J. G. Social Bookmarking                   What's this?

Salvage Therapy for CLL and the Role of Stem Cell Transplantation

Correspondence: John G. Gribben, MD, DSc, Barts and The London School of Medicine, St. Bartholomew’s Hospital, 45 Little Britain, London England EC1A 7BE, United Kingdom; Phone: +44 (020) 76017457, Fax: +44 (020) 77963979, john.gribben{at}cancer.org.uk

Abstract

Chronic lymphocytic leukaemia (CLL) remains an incurable disease and, notwithstanding the excellent remission rates now achieved with purine analogs and monoclonal antibodies, the vast majority of patients with CLL are destined to relapse after primary treatment. The management of relapsed CLL patients is then dependent upon a number of factors, most importantly age, performance status, previous therapy administered, the response and duration of response to such therapy, and time from last therapy. Although prior therapy and response to such therapy are important factors in determining next therapy, it is often difficult to determine their importance from published studies. Furthermore, the goal of therapy, whether palliative or aggressive, must also be weighed into the decision when deciding on the next line of treatment. With many potential treatments available, the sequence of treatments and the timing of procedures such as stem cell transplantation remain controversial and are the focus of ongoing clinical trials.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?